Judicial Scrutiny of Pharmaceutical Pricing: Addressing Ethical Disparities in Healthcare Access
The Supreme Court has raised concerns over the wide gap between the Price to Retailer (PTR) and Maximum Retail Price (MRP) of essential medicines, emphasizing the need for greater corporate accountability in healthcare.
The Supreme Court’s recent intervention regarding the significant price disparities between the Price to Retailer (PTR) and the Maximum Retail Price (MRP) of essential drugs, particularly life-saving cancer medications, marks a critical juncture in the discourse on healthcare affordability in India. The judiciary has highlighted that while market dynamics influence pricing, the current gap often places an undue financial burden on patients, effectively undermining the right to health.
This issue brings to the fore the tension between corporate profit-seeking and the ethical imperative of ensuring accessible healthcare. In the Indian context, where out-of-pocket expenditure remains a primary driver of poverty, the pricing strategies of pharmaceutical companies are not merely commercial decisions but have profound socio-economic consequences. The court’s critique suggests that existing regulatory frameworks may be insufficient in curbing predatory pricing practices that inflate costs before a drug reaches the end consumer.
For policymakers, this development underscores the necessity of strengthening the National Pharmaceutical Pricing Authority (NPPA) and revisiting the Drug Price Control Orders (DPCO). The focus must shift toward ensuring that the supply chain, from manufacturer to retailer, operates with transparency. Furthermore, this judicial observation aligns with the broader constitutional mandate of the state to provide affordable healthcare services, as envisioned under the Directive Principles of State Policy. As India strives for universal health coverage, the alignment of corporate governance with public welfare becomes non-negotiable. The judiciary’s stance serves as a reminder that in the healthcare sector, the 'profit motive' must be balanced against the 'humanitarian mandate' to ensure that essential treatments remain within the reach of the vulnerable sections of society.
Continue reading — free with login
JeetoBharat publishes daily UPSC current affairs mapped to the Mains syllabus. Log in to read full articles.
Log in to read full articleNo credit card required. Free registered users get unlimited access.
This article was curated using AI. While we strive for accuracy, please verify critical facts from official sources.